Ionis, Novartis’ Key Experimental Heart Drug Fails in Late-Stage Trial

Ionis, Novartis’ key experimental heart drug fails in late-stage trial

Sept 4 (Reuters) - Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a ​cholesterol-carrying particle in heart patients ‌failed in a late-stage trial, the companies said on Friday. Shares of Ionis fell 6% in aftermar...

Ionis Pharmaceuticals falls after Pelacarsen fails key phase 3 heart trial

Ionis/Novartis pelacarsen Phase 3 Lp(a)HORIZON missed its primary endpoint despite lowering Lp(a); IONS shares fell.

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to pl…

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling. The post Novartis, Ionis…